SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-20-135621
Filing Date
2020-05-07
Accepted
2020-05-07 07:44:40
Documents
15
Period of Report
2020-05-06
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d922186d8k.htm   iXBRL 8-K 49267
2 EX-10.1 d922186dex101.htm EX-10.1 212346
3 EX-99.1 d922186dex991.htm EX-99.1 9710
7 GRAPHIC g922186g0507092321506.jpg GRAPHIC 2579
  Complete submission text file 0001193125-20-135621.txt   449061

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA apls-20200506.xsd EX-101.SCH 3065
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE apls-20200506_lab.xml EX-101.LAB 17372
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE apls-20200506_pre.xml EX-101.PRE 10949
14 EXTRACTED XBRL INSTANCE DOCUMENT d922186d8k_htm.xml XML 3208
Mailing Address 100 FIFTH AVENUE WALTHAM MA 02451
Business Address 100 FIFTH AVENUE WALTHAM MA 02451 617-977-5700
Apellis Pharmaceuticals, Inc. (Filer) CIK: 0001492422 (see all company filings)

IRS No.: 271537290 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38276 | Film No.: 20854612
SIC: 2834 Pharmaceutical Preparations